The Asia Pacific Filgrastim Market would witness market growth of 9.4% CAGR during the forecast period (2021-2027).
Factor like the rising population of cancer patients, especially in developing nations like China and India, would unlock bright prospects for the Filgrastim market in the coming years. Although, the high cost attached to these biologics and strict regulatory compliance for the approval of biosimilars in developed nations would hamper the growth of the filgrastim market in the forecast years.
There are several biosimilars research going on across the world, which would accelerate the growth of the market. In addition, the availability of strong pipeline drugs is also estimated to support the growth of the filgrastim market over the forecast period.
One of the major factors augmenting the demand for filgrastim in this region is the increasing cases of cancer in developing nations like India and China. Governments across this region are taking many initiatives to aware people of the early treatment, which is estimated to propel the growth of the regional filgrastim market in the forecast period. However, many people with a low-income level cannot afford treatment for various chronic diseases, especially cancer. This would restrict the demand for filgrastim in the regional market.
Furthermore, as the healthcare system of this region is becoming stronger and governments are introducing better and cheaper healthcare facilities for the people, the demand for filgrastim would increase across this region. Although, the side effects of using filgrastim and the availability of various better alternatives would hinder the growth of the regional filgrastim market during the forecast period.
The China market dominated the Asia Pacific Filgrastim Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $60.3 million by 2027. The Japan market is experiencing a CAGR of 10.4% during (2021 - 2027). Additionally, The India market would witness a CAGR of 10.4% during (2021 - 2027).
Based on Drug Type, the market is segmented into Biosimilar and Biologic. Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Filgrastim Market is Projected to reach USD 953.4 million by 2027, at a CAGR of 8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksöz Group
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
By Indication
- Chemotherapy induced Neutropenia
- Chronic Neutropenia and
- Other Indications
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies and
- Online Pharmacies
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Amgen, Inc.
- Pfizer, Inc.
- Novartis AG
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Cadila Healthcare Ltd. (Zydus Cadila)
- Apotex, Inc.
- Toksöz Group
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Filgrastim Market, by Drug Type
1.4.2 Asia Pacific Filgrastim Market, by Indication
1.4.3 Asia Pacific Filgrastim Market, by Distribution Channel
1.4.4 Asia Pacific Filgrastim Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Filgrastim Market by Drug Type
3.1 Asia Pacific Biosimilar Market by Country
3.2 Asia Pacific Biologic Market by Country
Chapter 4. Asia Pacific Filgrastim Market by Indication
4.1 Asia Pacific Chemotherapy induced Neutropenia Market by Country
4.2 Asia Pacific Chronic Neutropenia Market by Country
4.3 Asia Pacific Other Indications Market by Country
Chapter 5. Asia Pacific Filgrastim Market by Distribution Channel
5.1 Asia Pacific Hospital Pharmacies Market by Country
5.2 Asia Pacific Retail Pharmacies Market by Country
5.3 Asia Pacific Online Pharmacies Market by Country
Chapter 6. Asia Pacific Filgrastim Market by Country
6.1 China Filgrastim Market
6.1.1 China Filgrastim Market by Drug Type
6.1.2 China Filgrastim Market by Indication
6.1.3 China Filgrastim Market by Distribution Channel
6.2 Japan Filgrastim Market
6.2.1 Japan Filgrastim Market by Drug Type
6.2.2 Japan Filgrastim Market by Indication
6.2.3 Japan Filgrastim Market by Distribution Channel
6.3 India Filgrastim Market
6.3.1 India Filgrastim Market by Drug Type
6.3.2 India Filgrastim Market by Indication
6.3.3 India Filgrastim Market by Distribution Channel
6.4 South Korea Filgrastim Market
6.4.1 South Korea Filgrastim Market by Drug Type
6.4.2 South Korea Filgrastim Market by Indication
6.4.3 South Korea Filgrastim Market by Distribution Channel
6.5 Singapore Filgrastim Market
6.5.1 Singapore Filgrastim Market by Drug Type
6.5.2 Singapore Filgrastim Market by Indication
6.5.3 Singapore Filgrastim Market by Distribution Channel
6.6 Malaysia Filgrastim Market
6.6.1 Malaysia Filgrastim Market by Drug Type
6.6.2 Malaysia Filgrastim Market by Indication
6.6.3 Malaysia Filgrastim Market by Distribution Channel
6.7 Rest of Asia Pacific Filgrastim Market
6.7.1 Rest of Asia Pacific Filgrastim Market by Drug Type
6.7.2 Rest of Asia Pacific Filgrastim Market by Indication
6.7.3 Rest of Asia Pacific Filgrastim Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Amgen, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.4 Novartis AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Dr. Reddy’s Laboratories Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.5.2 Product Launches and Product Expansions:
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Cadila Healthcare Ltd. (Zydus Cadila)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Apotex, Inc.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Product Launches and Product Expansions:
7.10 Toksöz Group
7.10.1 Company Overview
TABLE 1 Asia Pacific Filgrastim Market, 2017 - 2020, USD Million
TABLE 2 Asia Pacific Filgrastim Market, 2021 - 2027, USD Million
TABLE 3 Asia Pacific Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 4 Asia Pacific Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 5 Asia Pacific Biosimilar Market by Country, 2017 - 2020, USD Million
TABLE 6 Asia Pacific Biosimilar Market by Country, 2021 - 2027, USD Million
TABLE 7 Asia Pacific Biologic Market by Country, 2017 - 2020, USD Million
TABLE 8 Asia Pacific Biologic Market by Country, 2021 - 2027, USD Million
TABLE 9 Asia Pacific Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 10 Asia Pacific Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 11 Asia Pacific Chemotherapy induced Neutropenia Market by Country, 2017 - 2020, USD Million
TABLE 12 Asia Pacific Chemotherapy induced Neutropenia Market by Country, 2021 - 2027, USD Million
TABLE 13 Asia Pacific Chronic Neutropenia Market by Country, 2017 - 2020, USD Million
TABLE 14 Asia Pacific Chronic Neutropenia Market by Country, 2021 - 2027, USD Million
TABLE 15 Asia Pacific Other Indications Market by Country, 2017 - 2020, USD Million
TABLE 16 Asia Pacific Other Indications Market by Country, 2021 - 2027, USD Million
TABLE 17 Asia Pacific Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 18 Asia Pacific Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 19 Asia Pacific Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 20 Asia Pacific Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 21 Asia Pacific Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 22 Asia Pacific Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 23 Asia Pacific Online Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 24 Asia Pacific Online Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 25 Asia Pacific Filgrastim Market by Country, 2017 - 2020, USD Million
TABLE 26 Asia Pacific Filgrastim Market by Country, 2021 - 2027, USD Million
TABLE 27 China Filgrastim Market, 2017 - 2020, USD Million
TABLE 28 China Filgrastim Market, 2021 - 2027, USD Million
TABLE 29 China Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 30 China Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 31 China Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 32 China Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 33 China Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 34 China Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 35 Japan Filgrastim Market, 2017 - 2020, USD Million
TABLE 36 Japan Filgrastim Market, 2021 - 2027, USD Million
TABLE 37 Japan Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 38 Japan Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 39 Japan Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 40 Japan Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 41 Japan Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 42 Japan Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 43 India Filgrastim Market, 2017 - 2020, USD Million
TABLE 44 India Filgrastim Market, 2021 - 2027, USD Million
TABLE 45 India Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 46 India Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 47 India Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 48 India Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 49 India Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 50 India Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 51 South Korea Filgrastim Market, 2017 - 2020, USD Million
TABLE 52 South Korea Filgrastim Market, 2021 - 2027, USD Million
TABLE 53 South Korea Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 54 South Korea Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 55 South Korea Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 56 South Korea Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 57 South Korea Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 58 South Korea Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 59 Singapore Filgrastim Market, 2017 - 2020, USD Million
TABLE 60 Singapore Filgrastim Market, 2021 - 2027, USD Million
TABLE 61 Singapore Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 62 Singapore Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 63 Singapore Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 64 Singapore Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 65 Singapore Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 66 Singapore Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 67 Malaysia Filgrastim Market, 2017 - 2020, USD Million
TABLE 68 Malaysia Filgrastim Market, 2021 - 2027, USD Million
TABLE 69 Malaysia Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 70 Malaysia Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 71 Malaysia Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 72 Malaysia Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 73 Malaysia Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 74 Malaysia Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 75 Rest of Asia Pacific Filgrastim Market, 2017 - 2020, USD Million
TABLE 76 Rest of Asia Pacific Filgrastim Market, 2021 - 2027, USD Million
TABLE 77 Rest of Asia Pacific Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 78 Rest of Asia Pacific Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 79 Rest of Asia Pacific Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 80 Rest of Asia Pacific Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 81 Rest of Asia Pacific Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 82 Rest of Asia Pacific Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 83 Key Information – Abbott Laboratories
TABLE 84 Key Information – Amgen, Inc.
TABLE 85 Key Information – Pfizer, Inc.
TABLE 86 Key Information – Novartis AG
TABLE 87 key information – Dr. Reddy’s Laboratories Ltd.
TABLE 88 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 89 Key Information – Kyowa Kirin Co., Ltd.
TABLE 90 Key Information – Cadila Healthcare Ltd.
TABLE 91 Key Information – Apotex, Inc.
TABLE 92 Key Information – Toksöz Group
List of Figures
FIG 1 Methodology for the research